• Phil Taylor
• 06 Mar, 2019

The Cambridge, Massachusetts, biotech—which was one of our Fierce 15 winners last year—says the new funding will be used to expand its pipeline of development programs, refine its technology platforms and add to its headcount with additional “scientific and technical leadership.” Beam’s take on CRISPR is that that its approach to the technology is more precise than other genome editing techniques and can target just one base—A, G, C or T—out of billions.
Read more...